Opinions
Genevieve Roch-Decter
Khiron Life Sciences
KHRN-X
COMMENT
Jun 19, 2018
N/A
Stock price when the opinion was issued
agriculture
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
WATCH
He got stopped out of this. If you still own it, wait and hold. Cannabis is going through a normal consolidation. Maybe average down during tax-loss selling. He still likes it. Has a $3 target. They're becoming more of a marketing company and getting into pharmaceutical. They're in Colombia where CBD dominates the weed sector which will be a stepping stone to the rest of the world. Also, in Colombia the energy cost is zero.
agriculture
WATCH
He likes the company still. Out of Latin America, they will probably take the lead. The sector is going through consolidation and it is a time to go shopping. He would look more at Charlotte's Web who has solid earnings. However, below $1.00 there is still value for it. Latin America doesn't have the same perception there than here. They just got licenses from Brazil and Colombia. (Analysts’ price target is $3.25)
agriculture
Advertising
They are focused on the medical market in Columbia and more generally in Latin America. They are positioned to be one of the first Columbia-based companies to have product in the domestic market. Their CEO used to manage infrastructure projects for SNC. The other co-founder launched Advil into the country. Another executive has years of experience in the US Drug Enforcement Agency. This is a knowledgeable management team. They plan to replicate their model of doctor engagement throughout South America and Mexico.